Cargando…
External control cohorts for the single-arm LIBRETTO-001 trial of selpercatinib in RET+ non-small-cell lung cancer
BACKGROUND: Data for selpercatinib [a selective REarranged during Transfection (RET) inhibitor] from a single-arm trial (LIBRETTO-001, NCT03157128) in RET-fusion-positive advanced/metastatic non-small-cell lung cancer (NSCLC) were used in combination with external data sources to estimate comparativ...
Autores principales: | Rolfo, C., Hess, L.M., Jen, M.-H., Peterson, P., Li, X., Liu, H., Lai, Y., Sugihara, T., Kiiskinen, U., Vickers, A., Summers, Y. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9434413/ https://www.ncbi.nlm.nih.gov/pubmed/35930972 http://dx.doi.org/10.1016/j.esmoop.2022.100551 |
Ejemplares similares
-
Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non–Small Cell Lung Cancers on the LIBRETTO-001 Trial
por: Subbiah, Vivek, et al.
Publicado: (2021) -
Selpercatinib in patients with RET fusion positive non-small cell lung cancer: updated follow-up of the LIBRETTO-001 phase I/II trial
por: Stinchcombe, Thomas E.
Publicado: (2023) -
LIBRETTO-531: a phase III study of selpercatinib in multikinase inhibitor-naïve RET-mutant medullary thyroid cancer
por: Wirth, Lori J, et al.
Publicado: (2022) -
Selpercatinib in Patients With RET Fusion–Positive Non–Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial
por: Drilon, Alexander, et al.
Publicado: (2023) -
Efficacy and safety of selpercatinib in Chinese patients with
advanced RET-altered thyroid cancers: results from the phase II
LIBRETTO-321 study
por: Zheng, Xiangqian, et al.
Publicado: (2022)